+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07175428

Safety Evaluation of REGN7508 and REGN9933 Compared to Apixaban for Adults With Atrial Fibrillation

Led by Regeneron Pharmaceuticals · Updated on 2026-10-21

1200

Participants Needed

89

Research Sites

10 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying two experimental drugs, REGN7508 and REGN9933, in people with atrial fibrillation, a condition where the heart beats irregularly and too fast. The study aims to see how these drugs work to prevent blood clots compared to apixaban, a currently available medicine. The research also looks at potential side effects, how well the drugs reduce stroke risk, drug levels in the blood, and whether the body develops antibodies that might affect the drugs action or safety. Participants will be randomly assigned to receive either REGN7508, REGN9933, or apixaban. All treatments are given according to the study protocol. The study lasts about 12 weeks for the main bleeding safety measurements, with some evaluations continuing up to about 25 weeks to monitor adverse events, antibody development, and blood drug concentrations. Throughout the study, participants will have regular assessments to check for bleeding events, strokes, and treatment side effects. Blood tests will measure drug levels and blood clotting times. Researchers will track safety and effectiveness by comparing bleeding incidents and other outcomes between the different treatments. The total participation time covers the treatment period and follow-up visits up to about 25 weeks.

CONDITIONS

Brief Title

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here